Project Grant R01CA108854

This National Cancer Institute (NCI) Project Grant, awarded under the Cancer Research Manpower program (CFDA 93.398), provides $107,948 to Weill Medical College of Cornell University to conduct research on the functional consequences of mutations in the ZFP36L2 gene and its impact on the tumor immune microenvironment in colorectal cancer. The research aims to delineate how ZFP36L2 regulates the inflammatory secretome of colorectal cancer cells (Aim 1) and assess the impact of ZFP36L2 mutations...

The National Cancer Institute awarded a $406,611 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives of this 5-year research project are to: 1) characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids, 2) develop and evaluate highly...

This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms of developmental reprogramming in colorectal cancer (CRC). The key objectives are to identify regulators of fetal gene reactivation in CRC cells, determine if the transcription factor SOX9 directly controls fetal gene expression, and evaluate the...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will support research to investigate the role of the GRAIL gene in controlling intestinal inflammation and its link to colorectal cancer development. The $163,500 award, running from July 1, 2024 to June 30, 2026, will fund studies to determine how GRAIL expression in T follicular helper (Tfh) cells impacts intestinal homeostasis and tumor...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Nebraska Medical Center (UNMC) to assess strategies for targeting transcriptional co-activators in colorectal cancer. The $439,367 award will fund a 5-year research project focused on understanding how the transcriptional coactivator PGC-1B promotes the survival of colorectal cancer cells, particularly in tumors with K-RAS mutations. The project aims to identify...

This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...

This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award to the Icahn School of Medicine at Mount Sinai in the amount of $560,297 will fund a 5-year research project to functionally characterize "oncofetal stem cells" in colorectal cancer (CRC). The project aims to: Generate reporters to track the dynamics of CRC stem cell populations, including oncofetal stem cells and LGR5+ cancer stem cells. The researchers will then use these reporters coupled to a...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $281,606.00 in funding to New York University School of Medicine for a 5-year research project titled "Harnessing Human Gut-Derived Bacteroides to Drive Systemic Anti-Tumor Immunity." The research aims to clarify the mechanisms by which certain gut bacteria can elicit anti-tumor immune responses in lung cancer, even in the absence of immunotherapy. The project will utilize a...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $1,224,644 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the role of the B7-H4 protein and its interaction with the TGF-beta pathway in intrahepatic cholangiocarcinoma (CCA), a rare and deadly form of liver cancer. The key objectives are to: 1) Elucidate the molecular mechanisms by which B7-H4 promotes CCA cell growth, motility, and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding to Synthis Therapeutics, Inc. to develop SYN101, a novel immune cell-targeted TGF-β therapy for cancer patients. The $1,157,954 award, spanning September 2024 to August 2026, will support in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic analyses of SYN101. The goal is to generate preclinical data to support the advancement of this first-in-class immune cell-targeted...